Biotech venture capital investments in public equities and performance
Requires Subscription or Fee PDF

Keywords

Venture capital
venture investments in public equity
VIPE
biotechnology

Abstract

This study examines a large sample of venture investments in public equities (VIPEs) in the biotechnology and pharmaceutical industry over the period 1995-2014. The results of the study are threefold. First, and contrary to widely held beliefs, there has been no significant increase in the number of VIPEs over time. In fact, both in terms of dollar amount as well as the number of VIPE transactions have actually went down post the record year in 2009. Second, this study documents that returns profiles from the public venture capital market share many similarities to the returns in the private VC market: few big winners, but overall a high loss rate. Approximately seven investments out of ten in public firms generate a loss. Third, the analysis of private investments in public equities shows that venture capitalists outperform other competitors, such as hedge funds and mutual funds. From a management perspective, venture investments in public equity provide several benefits including providing an additional source of potential funding, aligning the investment horizon of venture capitalists with other long-term investors, certifying the quality of the firm and contributing to the long-term success.

https://doi.org/10.5912/jcb758
Requires Subscription or Fee PDF

References

Hellmann, T., and Puri, M. (2002) Venture capital and the professionalization of startâ€up firms: Empirical evidence. Journal of Finance 57(1): 169-197.

Brav, A., and Gompers, P. (1996) Myth or reality? The long-run underperformance of initial public offerings: Evidence from venture-and nonventure capital-backed companies. Journal of Finance 52(5): 1791-1821.

Harris, R., Jenkinson, T. and Kaplan, S. (2014) Private equity performance: What do we know? Journal of Finance 69(5): 1851-1882.

Mitchell, P. (2009) Venture capital shifts strategies, startups suffer. Nature Biotechnology 27(2): 103-104.

Hansen, S. (2014) Case Study: Algeta's lessons. Biocentury 22(6): A11-A13.

Mitchell, P. (2010) Microcap public biotechs access new pool of VC funding. Nature Biotechnology 28(7): 637-8.

Edelson, S. and Ward, M. (2009) Weathering (nuclear) winter. Biocentury 17(1): A1-A10.

Chaplinsky, S. And Haushalter, D. (2012) VIPE financing: Venture (capital) investments in public equity. In: D. Cumming (editor) Oxford Handbook of Venture Capital. New York: Oxford University Press, pp. 246-273.

Flanagan, M. (2009) Arrested by warrants. Biocentury 17(13): A1-A4.

Kaplan, S. And Schoar, A. (2005) Private equity performance: Returns, persistence, and capital flows. Journal of Finance 60(4): 1791-1823.

Lerner, J. (1994) Venture capitalists and the decision to go public. Journal of Financial Economics 35(3): 293-316.

Ball, E., Chiu, H. and Smith R. (2011) Can VCs time the market? An analysis of exit choice for venture-backed firms. Review of Financial Studies 24(9): 3105-3138.

Booth, B. and Salehizadeh, B. (2011) In defense of life sciences venture investing. Nature Biotechnology 29(7): 579-583.

Pastor, L. and Stambaugh, R. (2003) Liquidity risk and expected stock returns. Journal of Political Economy 111(3): 642-685.

Dai, N. (2007) Does investor identity matter? An empirical examination of investments by venture capital funds and hedge funds in PIPEs. Journal of Corporate Finance 13(4): 538-563.

Brav, A., Geczy, C. and Gompers, P. (2000) Is the abnormal return following equity issuances anomalous? Journal of Financial Economics 56(2): 209-249.

Fama, E. and French, K. (1993) Common risk factors in the returns on stocks and bonds. Journal of Financial Economics 33(1): 3-56.

Carhart, M. (1997) On persistence in mutual fund performance. Journal of Finance 52(1): 57-82.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.